The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
04-Oct-16
$223 million
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Target:
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
03-Apr-06
$3.7 billion
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Target:
Verizon Communications Inc.
![Mexico Mexico flag](https://www.greenhill.com/sites/default/files/mexico.gif)
Acquiror:
América Móvil and Telmex
(various assets)
Provided independent valuation services in connection with the acquisition by América Móvil and Telmex of a 100% stake in Verizon Dominicana, an approximate 52% stake in Telecomunicaciones de Puerto Rico and an approximate 28.5% stake in Compania Anónima Nacional Teléfonos de Venezuela